Clinical Trials Logo

Myelodysplastic Syndromes clinical trials

View clinical trials related to Myelodysplastic Syndromes.

Filter by:

NCT ID: NCT04810611 Terminated - Clinical trials for Myelodysplastic Syndromes

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Start date: June 18, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study was to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.

NCT ID: NCT04762875 Terminated - Clinical trials for Acute Lymphoblastic Leukemia

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

Start date: June 16, 2021
Phase: Phase 2
Study type: Interventional

This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies. MGTA-145, the new medicine, will be given with plerixafor.

NCT ID: NCT04691141 Terminated - Clinical trials for Myelodysplastic Syndrome

A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)

HATCH
Start date: February 23, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ⅰ/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and above Myelodysplastic Syndrome (MDS) Patients after Failure of Hypomethylating Agent (HMA)-based Therapy.

NCT ID: NCT04639024 Terminated - Clinical trials for Acute Myeloid Leukemia (AML)

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Start date: December 7, 2021
Phase: Phase 2
Study type: Interventional

This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation. ADCT-301 will be administered on Days 1, 8 and 15 with blood tests following study drug infusion. Patients will have a bone marrow biopsy at the end of cycle 2/before cycle 3 to see how they are responding to the study drug. Patients will be followed for approximately every 12 weeks from the last disease assessment for up to 1 year from completion of therapy. There are risks to this study drug. Some risks include: decrease in certain blood cells, weight loss, loss of appetite, rash and Guillain-Barre syndrome, where the immune system attacks and damages nerves.

NCT ID: NCT04638309 Terminated - Clinical trials for Myelodysplastic Syndromes

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Start date: September 20, 2021
Phase: Phase 1
Study type: Interventional

Phase 1 study evaluating the safety and efficacy of APR-548 in combination with Azacitidine for the treatment of TP53-Mutant Myelodysplastic Syndromes.

NCT ID: NCT04631211 Terminated - Clinical trials for Myelodysplastic Syndromes

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Start date: March 5, 2021
Phase: Phase 2
Study type: Interventional

This prospective, multicenter, randomized, open-label, Phase 2, parallel, dose ranging, multidose trial will enroll patients into 3 Thrombosomes dose groups and 1 control liquid stored platelets (LSP) group in order to evaluate, in a dose-escalation manner, the safety, and impact on bleeding, and the preliminary effect on coagulation measures of increasing doses of allogeneic Thrombosomes in comparison to standard of care, LSP.

NCT ID: NCT04623996 Terminated - Clinical trials for Anemia in Myelodysplastic Syndromes

A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

Start date: December 28, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate preliminary safety and efficacy of TP-0184 to treat anemia when administered to adult patients with Revised International Prognostic Scoring System (IPSS-R) low or intermediate risk MDS. The recommended Phase 2 dose (RP2D) will be determined by the maximum tolerated dose (MTD) or maximum administered dose (MAD) in the Phase 1 portion of the study.

NCT ID: NCT04526288 Terminated - Clinical trials for Acute Myeloid Leukemia

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Start date: August 9, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of CPX-351 followed by donor stem cell transplantation versus immediate donor stem cell transplantation in treating patients with high-grade myeloid cancers with measurable residual disease. Chemotherapy drugs, such as CPX-351, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before donor stem cell transplantation may help kill cancer cells in the body and make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.

NCT ID: NCT04326764 Terminated - Clinical trials for Myelodysplastic Syndromes (MDS)

Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Start date: July 24, 2018
Phase: Phase 3
Study type: Interventional

Aim of this prospective randomized trial is to compare maintenance treatment with panobinostat interspersed with donor lymphocyte infusions (DLI) versus the standard approach of pre-emptive DLI alone in patients with poor-risk AML/MDS having favorably received an allogeneic HSCT followed by engraftment, donor chimerism and hematopoietic reconstitution.

NCT ID: NCT04313881 Terminated - Clinical trials for Myelodysplastic Syndromes

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

ENHANCE
Start date: September 9, 2020
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).